TMPRSS2 and COVID-19: Valproic acid can reduce the expression of angiotensin-converting enzyme 2 and transmembrane serine protease 2 required for SARS-CoV-2 virus entry (53), and reduces pathological atrial remodeling thereby preventing the development of AF, which may be a candidate for COVID-19 and AF therapy (54).